RespireRx

RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury

Retrieved on: 
Mittwoch, März 20, 2024
OTC Markets Group, Neurogenic bladder dysfunction, Death, Ampakine, DOI, Tetraplegia, Rat, Incidence, Bourbeau, Risk, Bruise, Patient, Research, University, Bladder cancer, Quality of life, Pleasure, EMG, Alom, Catheter, AMPA, Injury, Interim, CSO, Bangladesh Technical Education Board, Urinary tract infection, Respiration, Animal, Kidney, SCI, Rana, RespireRx

Restoration of bladder function is ranked as one of the highest priorities by individuals with SCI (Bourbeau et al., Spinal Cord 58:1216–1226; 2020).

Key Points: 
  • Restoration of bladder function is ranked as one of the highest priorities by individuals with SCI (Bourbeau et al., Spinal Cord 58:1216–1226; 2020).
  • Current treatment approaches usually require interventions such as catheterization for urinary voiding, which have their own set of risks and potentially significant set of complications.
  • The present paper, entitled “Acute ampakines increase voiding function and coordination in a rat model of SCI” (Rana, Alom et al.
  • We believe that this research has the potential to represent a novel, breakthrough in the treatment of SCI, which is badly needed.”

RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine

Retrieved on: 
Dienstag, Februar 13, 2024
Therapy, NINDS, RespireRx, GABAA, NIH, Neuropathic pain, Epilepsy, Addiction, Neuron, Narcotic, Female, Rat, OTC Markets Group, Drug discovery, Analgesic, Disability studies, Interim, University, PSPP, Pain management, Chronic pain, Research fellow, Patient, Heart, Initiative, Male, Hypoventilation, IND, DRS, Laboratory, Research, Pharmaceutical industry

Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management.

Key Points: 
  • Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management.
  • The PSPP program, part of the NIH HEAL Initiative, evaluates non-opioid assets in a battery of established preclinical pain models.
  • These observations were made with both male and female rats in two measures each, in models of post-incision pain and spinal nerve ligation-induced persistent neuropathic pain.
  • These data trigger the advancement of KRM-II-81 within the NIH PSPP program where additional disease-specific pain models will be evaluated.

RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors

Retrieved on: 
Montag, Januar 22, 2024
OTC Markets Group, Life, Regenerative medicine, Tetraplegia, RespireRx, Health, Science, Pain management, Society, Platelet-rich plasma, MBA, Epilepsy, Interim, Ampakine

Dr. Nasiek is a dedicated anesthesiologist with expertise in anesthesiology and interventional pain management.

Key Points: 
  • Dr. Nasiek is a dedicated anesthesiologist with expertise in anesthesiology and interventional pain management.
  • Dr. Nasiek is board certified by the American Board of Anesthesiology, the American Board of Pain Medicine and the American Board of Interventional Pain Physicians.
  • Dr. Nasiek is also a Life Member of the American Society of Interventional Pain Physicians and a Member of the International Spine Intervention Society.
  • I am excited about the science, the clinical development strategies and the potential breakthroughs for patient care,” said Dr. Nasiek.

RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development

Retrieved on: 
Montag, Dezember 11, 2023
Amylin Pharmaceuticals, Biotechnology, Sale, Eli Lilly, Strategic management, OTC Markets Group, Therapy, Business development, RespireRx, Decision Sciences, Dronabinol, Eli Lilly and Company

Mr. Clodfelter will initially lead the business development efforts with respect to dronabinol, the lead asset of ResolutionRx Ltd, a wholly-owned Australian subsidiary of the Company.

Key Points: 
  • Mr. Clodfelter will initially lead the business development efforts with respect to dronabinol, the lead asset of ResolutionRx Ltd, a wholly-owned Australian subsidiary of the Company.
  • Mr. Clodfelter will collaborate with Jeff Eliot Margolis, the Company’s Senior Vice President, Chief Financial Officer, Treasurer and Secretary in driving these efforts.
  • He previously held positions at Eli Lilly and Co. in Corporate Strategy and Business Development.
  • He was at Amylin Pharmaceuticals in New Product Planning and Decision Sciences and was involved in multiple business development activities.

RespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services

Retrieved on: 
Donnerstag, Oktober 12, 2023
Master service agreement, Partnership, CSO, MSA, Dronabinol, RespireRx, GMP, OTC Markets Group, Obstructive sleep apnea, Australian Company Number, Pharmaceutical industry

The initial services relate to ResolutionRx’s repurposing of dronabinol and its development program for obstructive sleep apnea pursuant to which Ab Initio will, among other things, manufacture and test our new dronabinol lipid nanoparticle formulation for pharmacokinetic, pharmacodynamic, and pivotal clinical trials, as well as ultimately for commercialization.

Key Points: 
  • The initial services relate to ResolutionRx’s repurposing of dronabinol and its development program for obstructive sleep apnea pursuant to which Ab Initio will, among other things, manufacture and test our new dronabinol lipid nanoparticle formulation for pharmacokinetic, pharmacodynamic, and pivotal clinical trials, as well as ultimately for commercialization.
  • “The importance of this partnership cannot be overstated,” said Arnold Lippa, Ph.D., co-CEO and CSO of ResolutionRx and CEO and CSO of RespireRx.
  • “With its formulation expertise and GMP manufacturing facilities, Ab Initio will complete our original laboratory experiments to determine a final, optimum dronabinol formulation, scale up and manufacture the chosen formulation for clinical use.
  • The lipid nanoparticle technology not only represents a major step forward in the development of dronabinol, but the potential for more widespread use for insoluble or poorly soluble drugs.”

RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company

Retrieved on: 
Mittwoch, August 9, 2023
Transfer, Radium, Communication, Second Amendment to the United States Constitution, Australian Company Number, University, Senior, Ingenu, Letter of intent, Intellectual property, Service, CSO, Research, License, Securities and Exchange Commission (Philippines), LOI, Sale, End-user license agreement, Patent, Hale v. Committee on Character and Fitness for the State of Illinois, University of Illinois Urbana-Champaign, Trustee, OTC, Security (finance), MISA, Letter, Obstructive sleep apnea, RespireRx, Pharmaceutical industry

The Exclusive License permits the sublicensor to grant written sublicenses of its rights under the Exclusive License.

Key Points: 
  • The Exclusive License permits the sublicensor to grant written sublicenses of its rights under the Exclusive License.
  • The Sublicense is essentially a direct pass-through of all of the rights and obligations associated with the Exclusive License to ResolutionRx as sublicensee from RespireRx as sublicensor.
  • In consideration for the License and Sublicense, ResolutionRx issued 25,000,000 Ordinary Shares of ResolutionRx to RespireRx pursuant to a stock transfer agreement plus the payment of US$1 to RespireRx.
  • Our service agreements with RespireRx and iNGENu will provide the needed infrastructure for operations that have recently begun.

ResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development Costs

Retrieved on: 
Mittwoch, Mai 24, 2023
Radium, OTC Markets Group, Interim, Letter, IPO, Australian Company Number, Senior, Ingenu, Letter of intent, CSO, Commission, Common stock, Clinical trial, Research, Australian Securities Exchange, Australian Research Data Commons, R, RespireRx, Research and Development Tax Incentive, Security (finance), Financial adviser

The Series A Shares are convertible, and upon conversion, shall at all times be paid with Ordinary Shares and not in cash.

Key Points: 
  • The Series A Shares are convertible, and upon conversion, shall at all times be paid with Ordinary Shares and not in cash.
  • Such listing will be either by IPO, backdoor (shell merger) or direct listing or another mutually agreed method.
  • The Cantheon investment will be exempt from registration under the applicable U.S. federal and state securities laws, rules and regulations.
  • “This financing is a crucial next step in the restructuring of RespireRx and the founding and funding of ResolutionRx.

RespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders

Retrieved on: 
Mittwoch, April 5, 2023
University College London, Learning, UCL, Pompe, UCL Department of Information Studies, OTC Markets Group, DRS, University of Wisconsin–Milwaukee, Disorder, Patient, University, Indiana University–Purdue University Indianapolis, Drug discovery, Ampakine, GRIA, Rafael Ampar, Memory, RespireRx, Pharmaceutical industry, Neuroscience, Pharmacology, Physiology

Positive therapeutic effects with RespireRx’s AMPAkines already have been reported in animal mutations modelling related disorders such as Pompe that also suffer from declines in AMPA receptor functioning.

Key Points: 
  • Positive therapeutic effects with RespireRx’s AMPAkines already have been reported in animal mutations modelling related disorders such as Pompe that also suffer from declines in AMPA receptor functioning.
  • The RespireRx team that will collaborate with Dr. Coombs, Prof. Farrant and Prof. Cull-Candy includes Drs.
  • Jeffrey M. Witkin and Rok Cerne, both of whom are RespireRx Research Fellows in addition to their academic affiliations at The University of Wisconsin-Milwaukee, Ascension St. Vincent Hospital and Indiana University/Purdue University, respectively.
  • The team has extensive expertise and are well known for their work in drug discovery and development, including novel analgesic, anxiolytic, anti-epileptic and anti-depressant drugs.

RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation.

Retrieved on: 
Montag, April 3, 2023
Epilepsy, GABA, Anticonvulsant, Tremor, GABAergic, OTC Markets Group, DRS, KPP, University of Wisconsin–Milwaukee, KRM, Essential tremor, Pain, Patient, University, Blood, Neuropathic pain, Indiana University–Purdue University Indianapolis, Irena Kosmowska, Drug discovery, CFO, ACS Omega, IND, RespireRx, Pharmaceutical industry

Like KRM-II-81, these analogs enhance GABAergic neurotransmission and function as orally-bioavailable anti-seizure agents in the absence of the sedation typically associated with GABA augmentation.

Key Points: 
  • Like KRM-II-81, these analogs enhance GABAergic neurotransmission and function as orally-bioavailable anti-seizure agents in the absence of the sedation typically associated with GABA augmentation.
  • In addition KRM-II-81 is active in relieving acute, chronic, and neuropathic pain in a number of models without developing tolerance or producing sedation.
  • 385:50-61 document the preclinical effects and tolerability of structural analogs of KRM-II-81.
  • In established rat models predicting efficacy in essential tremor and in tremor associated with Parkinson’s Disease, MP-III-024 was an effective anti-tremor compound.

ResolutionRx Ltd and RespireRx Pharmaceuticals Inc. Announce ResolutionRx’s Entry into a Services Agreement with iNGENu CRO Pty Ltd

Retrieved on: 
Mittwoch, März 1, 2023
Radium, Trade in Services Agreement, Safety, Australian Company Number, Australian Research Data Commons, Service, Research, OTC, Business, Australian Business Number, Argyreia nervosa, R, DTI, Consultant, Letter, Ingenu, Dronabinol, Research and Development Tax Incentive, Obstructive sleep apnea, RespireRx, D, ABN, Pharmaceutical industry, Bookkeeping, Commercial property, Audit

Collectively, ResolutionRx and RespireRx are leaders in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling.

Key Points: 
  • Collectively, ResolutionRx and RespireRx are leaders in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling.
  • iNGENu is a bespoke contract research organization focused on cannabinoid and psychedelic clinical research.
  • Entry into the Services Agreement with iNGENu.
  • Early preparation for a ResolutionRx initial public offering in Australia, and possibly other international markets at an appropriate future date.